Amgen Inc. (AMGN)

業務介紹

安進公司(Amgen Inc.)在全球範圍內發現、開發、製造和提供人類治療藥物。它專注於炎症、腫瘤/血液學、骨骼健康、心血管疾病、腎臟病學和神經科學領域。該公司的產品包括:

Enbrel用於治療斑塊性牛皮癬、類風濕性關節炎和銀屑病性關節炎;
Neulasta可降低癌症患者由於白細胞數量過低而感染的機會;
Prolia用於治療閱經後婦女的骨質疏鬆症;
Xgeva用於預防骨骼相關事件;
Otezla用於治療成人斑塊性牛皮癬、銀屑病性關節炎和貝赫切特病相關的口腔潰瘍;
Aranesp用於治療紅細胞數量偏低和貧血;
KYPROLIS用於治療復發或難治性多發性骨髓瘤的患者;
Repatha可降低心肌梗死、中風和冠狀動脈重建手術的風險。

該公司還銷售Nplate、Vectibix、MVASI、Parsabiv、EPOGEN、KANJINTI、BLINCYTO、Aimovig、EVENITY、AMGEVITA、Sensipar/Mimpara、NEUPOGEN、IMLYGIC、Corlanor和AVSOLA等產品。

安進公司的客戶包括醫療服務提供者,如醫生或其診所、透析中心、醫院和藥房。它通過藥品批發商和直接面向消費者的渠道分銷產品。

該公司與諾華制藥公司、UCB、拜耳健康護理公司、百濟神州、礼來公司、Datos Health和Verastem公司等公司有合作協議。它還與京都吉藥公司合作開發和商業化KHK4083,這是一種用於治療特應性皮炎和其他自身免疫性疾病的III期抗OX40全人源單克隆抗體。此外,它還與Neumora Therapeutics公司和Plexium公司有研發合作。

安進公司成立於1980年,總部位於加利福尼亞州千橡市。



Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

公司網址

https://www.amgen.com